Abstract: The present invention relates to stabilized medicaments containing thyroid hormone the stabilizing component of which is sodium thiosulfate in a mass ratio of thyroid hormone to sodium thiosulfate of 1:0.1 to 1:50 and processes for preparing such medicaments.

Abstract: Described are dry pharmaceutical preparations or clysters designed for rectal administration, which contain an active ingredient or mixture of active ingredients plus additives, and which are only reconstituted immediately before use by the addition of water, the volume of which can be selected to suit the particular patient. Such preparations are preferably marketed in graduated clyster flasks allowing the contents to be diluted with an amount of water appropriate to a particular patient.

Abstract: Formulations of oxypurinol and/or its alkali or alkaline earth salts in non-crystalline form, containing the active substance in the form of a solids dispersion with pharmacologically harmless adjuvants. They have more rapid and higher solubility than oxypurinol and/or its alkali or alkaline earth salts. They can be used for the preparation of drugs having high bioavailability of the active substance oxypurinol.

Abstract: Solid drug formulations for oral administration containing one or more dihydropyridines in doses of between 10 and 240 mg and suitable to be administered as a single dose per day for the treatment of circulatory disorders and high blood pressure.

Abstract: An improved form of administration of 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridine-dicarboxylic acid-dimethylester (i.e., Nifedipine) is provided in which the Nifedipine is molecularly dispersed wihtin a solidified melt of polyethylene glycols which are liquid, semi-solid and solid at room temperature. The weight ratio of liquid to non-liquid polyethylene glycols in the solidified melt ranges from about 7:23 to 23:7, the solidification temperature of the mixture ranges from about 25.degree. C. to 62.degree. C. and the mixture has a viscosity of from about 1 to 180,000 poise when measured at 20.degree. C. in admixture with up to about 40 percent by weight of water.

Abstract: A pharmaceutical combination preparation and method for the treatment of circulatory disturbances comprising a dihydropyridine of the formula ##STR1## in which --R.sub.1, is a CH.sub.3 --O--CH.sub.2 --CH.sub.2 -- or CH.sub.3 group; R.sub.2 is a ##STR2## or CH.sub.3 --CH.sub.2 -- group; R.sub.3 is 4, NO.sub.2 or CL; and R.sub.2 is NO.sub.2, H or CL; and pharmaceutically suitable salts thereof; as active substance A and Pentoxifylline as active substance B, the quantity ratios of A:B being from about 1:150 to about 1:2.